Novo Nordisk: EU approves diabetes tablet Rybelsus

(CercleFinance.com) - Danish drugmaker Novo Nordisk said on Monday that the European Commission has approved its type 2 diabetes tablet Rybelsus.


The marketing authorisation applies to all 27 member states and the UK, with a launch expected to take place in the second half of 2020, Novo said.

An analogue of the natural hormone GLP-1, Rybelsus is already approved in the US and Switzerland as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Copyright (c) 2020 CercleFinance.com. All rights reserved.